Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients (ACTivate)

NCT07516314 is registered in ClinicalTrials.gov with Anthony Sung, MD as lead sponsor.

NCT NCT07516314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07516314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients (ACTivate)
Lead sponsor
Anthony Sung, MD
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
April 30, 2031
Enrollment
476 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stem cell transplant patients